3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Burkitt Lymphoma
21
Lymphoma, Large B-Cell, Diffuse
18
Multiple Myeloma
16
Lymphoma, Non-Hodgkin
14
Leukemia, Myeloid, Acute
14
Lymphoma
12
Myelodysplastic Syndromes
11
Lymphoma, Follicular
11
Lymphoma, B-Cell
11
Recurrence
10
Ovarian Neoplasms
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Lymphoma, Mantle-Cell
8
Leukemia
8
Hodgkin Disease
8
Pancreatic Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Hematologic Neoplasms
6
Breast Neoplasms
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Biphenotypic, Acute
5
Anemia, Refractory, with Excess of Blasts
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Sarcoma, Ewing
4
Sarcoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Interventions
Bevacizumab
12
olaparib
10
Paclitaxel
10
Carboplatin
10
liposomal doxorubicin
7
Specimen Handling
7
Magnetic Resonance Spectroscopy
6
mirvetuximab soravtansine
4
Topotecan
4
Taxes
4
Immunoglobulin G
4
Gemcitabine
4
Disulfides
4
Biopsy
4
pembrolizumab
3
cediranib
3
Oxaliplatin
2
Doxorubicin
2
1-dodecylpyridoxal
2
tremelimumab
1
trastuzumab deruxtecan
1
sotorasib
1
sarilumab
1
palbociclib
1
niraparib
1
nilotinib
1
neratinib
1
irinotecan sucrosofate
1
ipatasertib
1
dehydroftorafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Cyclophosphamide
×
30 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled